Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis.

ABSTRACT:

Background

Venetoclax is clinically active in treating relapsed/refractory multiple myeloma (RRMM). This study evaluated the efficacy and safety of venetoclax or venetoclax with other agents in treating RRMM.

Methods

PubMed, Web of Science, Embase, and Cochrane Library were comprehensively searched. We included studies investigating the efficacy and safety of venetoclax or venetoclax with other agents in treating RRMM. Overall response rates (ORR), stringent complete response rates (sCR), complete response rates (CR), very good partial response rates (VGPR), partial response rates (PR), stable disease (SD), progressive disease (PD) and adverse events were synthesized using either a random-effects model or a fixed-effects model.

Results

A total of 7 clinical trials wit

SUBMITTER: Gao X 

PROVIDER: S-EPMC10623759 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature